logo

CVKD

Cadrenal·NASDAQ
--
--(--)
--
--(--)
2.69 / 10
Underperform

Corporate fundamentals are rated poor at 2.7/10. Key concerns include an elevated PB-ROE of 5.289 (group 4) and a negative Asset-MV of -0.506 (group 1), both signaling valuation risks. Although strong revenue growth (YoY 78.6% and 92.7%) offers some relief, the overall score remains low, indicating fundamental weakness and a challenging investment case.

Fundamental(2.69)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value-0.26
Score3/3
Weight30.91%
1M Return11.03%
Total operating revenue (YoY growth rate %)
Value78.62
Score3/3
Weight1.99%
1M Return0.88%
Inventory turnover ratio
Value47.88
Score2/3
Weight-2.57%
1M Return-1.23%
Profit-MV
Value0.47
Score2/3
Weight24.81%
1M Return8.99%
PB-ROE
Value5.29
Score0/3
Weight8.83%
1M Return3.36%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.51
Score2/3
Weight-2.68%
1M Return-1.25%
Operating revenue (YoY growth rate %)
Value92.79
Score2/3
Weight0.23%
1M Return0.10%
Asset-MV
Value-0.51
Score0/3
Weight16.76%
1M Return6.58%
Net profit / Total profit (%)
Value100.00
Score2/3
Weight-2.11%
1M Return-0.98%
Cash-MV
Value-0.07
Score2/3
Weight23.82%
1M Return8.80%
Is CVKD fundamentally strong?
  • CVKD scores 2.69/10 on fundamentals and holds a Premium valuation at present. Backed by its -200.47% ROE, 0.00% net margin, -0.93 P/E ratio, 4.87 P/B ratio, and -46.06% earnings growth, these metrics solidify its Underperform investment rating.